SU11274 is a selective, ATP-competitive inhibitor of MET receptor tyrosine kinase (IC50 = 20 nM; Sattler et al.) It shows good selectivity towards MET versus other receptor tyrosine kinases with IC50 values of 1.3 μM and 9.7 μM for kinase insert domain receptor (KDR) and fibroblast growth factor receptor-1 (FGFR1), respectively (Sattler et al.) It retains activity for certain MET mutants, for example H1112Y and M1268T (Berthou et al.)
Induces apoptosis and cell cycle arrest in TPR-MET-transformed mouse pre-B (Ba/F3) cells (Sattler et al.)
Inhibits cell viability and motility of human head and neck squamous cell carcinoma cell lines in vitro (Seiwert et al.)
Inhibits cell viability of c-MET-expressing human non-small cell lung carcinoma cell lines in vitro (Ma et al.)
